EUCTR2012-004124-38-GB进行中（未招募）不适用
Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 with Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected SubjectsRevised protocol 04, incorporating amendment 05 and administrative letter 02+ Pharmacogenetics Blood Sample Amendment 01 Site Specific, dated 28 Feb 2013
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Signed Written Informed Consent: The signed informed consent form.
- •2) Target Population
- •a) HIV-1 infected (clades B or C) subjects meeting the following criteria at the screening visit (within 30 days of enrollment):
- •i) Plasma HIV-1 RNA = 5,000 copies/mL (may be repeated for confirmation)
- •ii) Antiretroviral treatment naive (defined as <1 week of ARV treatment) or ART-experienced (protease inhibitor and/or maturation inhibitor naive)
- •iii) Subjects are not eligible for HIV-1 treatment based on the United States Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents or have declined initiation of cART
- •iv) CD4+ lymphocyte measurement = 200 cells/µL (may be repeated for confirmation)
- •v) In Parts A and B, all subjects are infected with clade B HIV-1 virus
- •vi) In Part C, all subjects are infected with clade C HIV-1 virus
- •b) Body Mass Index (BMI) of 18.0 to 35.0 kg/m2, inclusive. BMI = weight (kg)/m2
- •c) Subject Re-enrollment: This study permits the re-enrollment of a subject that has discontinued the study as a pre-treatment failure (ie, subject has not been randomized / has not been treated). If re-enrolled, the subject must be reconsented and re-numbered.
- •3) Age and Reproductive Status
- •a) Men and women, ages 18-55 years, inclusive for Parts A and C
- •b) Men, ages 18-55 years, inclusive for Part B
- •c) In Parts A and C, women of childbearing potential (WOCBP) must use method(s) of contraception based on the tables in Appendix 1. Because BMS-955176 may be a selective developmental toxicant and a potential teratogen, subjects must agree to the use of two methods of contraception, one method being highly effective and the other method being highly effective or less effective as defined in Appendix 1. The individual methods of contraception and duration should be determined in consultation with the investigator. WOCBP must follow instructions for birth control when the half life of the investigational drug is greater than 24 hours, contraception should be continued for a period of 30 days plus the time required for the investigational drug to undergo five half lives (a total of 38 days post the last dose). In addition, WOCBP must follow the methods of contraception at least 4 weeks prior to the first dose and during the treatment.
- •d) In Parts A and C, women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of investigational product.
- •e) In Parts A and C, women must not be breastfeeding
- •f) Men who are sexually active with WOCBP must use two methods of contraception, one method being highly effective and the other method being highly effective or less effective (listed in Appendix 1). The investigator shall review contraception methods and the time period that contraception must be followed. Men that are sexually active with WOCBP must follow instructions for birth control when the half life of the investigational drug is greater than 24 hours, contraception should be continued for a period of 90 days plus the time required for the investigational drug to undergo five half lives (for a total of 98 days post the last dose).
- •g) Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile; see Section 3.3.3 for the definition of WOCBP) and azoospermic men do not require contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
排除标准
- •1) Target Disease Exceptions
- •a) History of genotypic and/or phenotypic drug resistance testing showing resistance to protease inhibitors
- •i) Screening HIV-1 genotypic drug resistance testing at baseline showing primary protease inhibitor resistance mutations as defined by the presence of any of the following: D30N, M46I/L, I47V/A, G48V, I50L, I54M/L, Q58E, T74P, L76V, V82A/F/L/T/S, N83D, I84V, N88S, L90M
- •2) Medical History and Concurrent Diseases
- •a) Any significant acute or chronic medical illness which is not stable or is not controlled with medication or not consistent with HIV-1 infection.
- •b) Current or recent (within 3 months of study drug administration) gastrointestinal disease that, in the opinion of the Investigator or Medical Monitor, may impact on drug absorption.
- •c) Any major surgery within 4 weeks of study drug administration.
- •d) Acute diarrhea lasting = 1 day, within 3 weeks prior to randomization. Diarrhea will be defined as the passage of liquid feces and/or a stool frequency greater than three times per day.
- •e) Subjects with history of Gilbert’s syndrome.
- •f) Subjects with antiretroviral treatment within 12 weeks prior to screening
- •g) Subjects currently co-infected with hepatitis C or hepatitis B
- •h) Subjects previously received an HIV maturation inhibitor or HIV protease inhibitor
- •i) A personal history of clinically relevant cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or additional risk factors for torsades de pointes. A personal or family history of long QT syndrome.
- •j) Subjects who are unwilling to practice adequate infection protection during and after study participation to minimize potential for spread of HIV infection, including HIV which may have developed resistance to HIV maturation inhibitor and/or ATV. Such protections could include, but are not limited to behaviors to minimize potential for exposure to the subjects’ bodily fluids or initiation of cART therapy if indicated and recommended by a physician.
- •k) Any gastrointestinal surgery that could impact upon the absorption of study drug.
- •l) Donation of blood to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration (within 2 weeks for plasma only).
- •m) Blood transfusion within 4 weeks of study drug administration.
- •n) Inability to tolerate oral medication.
- •o) Inability to be venipunctured and/or tolerate venous access.
- •p) Smoking more than 10 cigarettes per day.
- •q) Recent (within 6 months of study drug administration) drug or alcohol abuse as defined in DSM IV, Diagnostic Criteria for Drug and Alcohol Abuse (Appendix 2).
- •r) Any other sound medical, psychiatric and/or social reason as determined by the investigator.
- •3) Physical and Laboratory Test Findings
- •a) Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations or not consistent with the subject’s degree of HIV infection.
- •b) Any of the following on 12-lead electrocardiogram (ECG) prior to study drug administration, confirmed by repeat.
- •i) PR = 210 msec
- •ii) QRS = 120 msec
- •iii) QT = 500 msec
- •iv) QTcF = 470 msec for women and = 450 msec for men
- •c) Evidence of second or third degree heart block prior to study drug, confirmed by repeat ECG.
- •d) Positive urine screen for drugs of abuse at either Screening or Day -1 without a valid prescription (subjects positive for cannabinoids and/or amphetamines wi
研究者
相似试验
进行中（未招募）
不适用
Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 and BMS-955176 with Atazanavir +/- Ritonavir in HIV-1 Infected SubjectsEUCTR2012-004124-38-DEBristol-Myers Squibb International Corporation
已完成
不适用
Randomized, placebo-controlled multiple dose study to evaluate the effect of hydroxychloroquine on the general immuno-competence in young and elderly healthy male volunteersNL-OMON49980Centre for Human Drug Research40
进行中（未招募）
1 期
A placebo-controlled, multiple dose, phase IIb, dose guiding trial to explore safety and tolerability of four weeks treatment with sulthiame in patients with moderate to severe obstructive sleep apneaModerate to severe obstructive sleep apneaMedDRA version: 20.0Level: LLTClassification code 10055577Term: Obstructive sleep apnea syndromeSystem Organ Class: 100000004855EUCTR2017-004767-13-SEDesitin Arzneimittel GmbH68
进行中（未招募）
1 期
study to evaluate the onset of pain response after administration of ketoprofen, in male and female subjects with acute pain after removal of a molar toothpain management in odontoiatryMedDRA version: 21.1Level: PTClassification code 10062132Term: Tooth extractionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2019-002114-38-ITDOMPé FARMACEUTICI S.P.A.120
尚未招募
不适用
Compare the Efficacy and Safety of Budesonide andFormoterol Fumarate Dihydrate Inhalation Aerosol80/4.5 mcg per Actuation in Asthma patientsCTRI/2019/10/021627Deva Holding AS